Dosing for Qfitlia™ (fitusiran) is guided by antithrombin levels¹

Antithrombin activity levels can be reliably measured^1,2

^* Do not initiate Qfitlia dosing if antithrombin activity is <60% at baseline.^1
† Additional measurements can be considered if the clinical status of the patient has changed.¹

Transitioning from factor replacement or BPA prophylaxis¹

Patients may continue their prior factor or BPA prophylaxis for the first 7 days of Qfitlia treatment. Seven days after the initial dose of Qfitlia, discontinue factor or BPA prophylaxis.

Dosing modification guidelines for Qfitlia¹

Antithrombin activity levels must be measured using an FDA-cleared antithrombin activity assay¹

• Patients taking Qfitlia can have these antithrombin measurements completed at no cost through a Sanofi-Labcorp Support Program^*
• Do not initiate Qfitlia if antithrombin activity is <60% at baseline¹
• There are many laboratory tests that measure antithrombin activity levels. Antithrombin testing for patients prescribed Qfitlia must be performed using an FDA-cleared antithrombin activity assay¹

How to administer Qfitlia—a video for patients

Watch this video to learn how patients can self-inject Qfitlia.